

MYLAN INC.  
Form 8-K  
March 17, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 17, 2014 (March 14, 2014)**

**MYLAN INC.**

**(Exact Name of Registrant as Specified in Charter)**

**Pennsylvania**  
**(State or Other Jurisdiction**  
**of Incorporation)**

**1-9114**  
**(Commission**  
**File Number)**

**25-1211621**  
**(I.R.S. Employer**  
**Identification No.)**

**15317**

**1000 Mylan Boulevard**  
**Canonsburg, PA**  
**(Address of Principal Executive Offices)** **(Zip Code)**  
**Registrant's telephone number, including area code: (724) 514-1800**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

**Item 5.02. Departure of Directors or Certain Officers.**

On March 14, 2014, Harry A. Korman, Executive Vice President and Chief Operating Officer, announced his retirement from Mylan Inc. ( Mylan or the Company ) effective July 1, 2014.

Mr. Korman joined Mylan in 1996, and has served the company with distinction and integrity throughout his tenure. Mr. Korman has been an important part of the leadership team that helped successfully transform Mylan from a U.S.-based generics business into a leading global pharmaceutical company. During his tenure, Mr. Korman helped drive significant growth in the Company's business, in terms of both revenues and product portfolio.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYLAN INC.

Date: March 17, 2014

By: /s/ John D. Sheehan  
John D. Sheehan  
Executive Vice President & Chief Financial Officer